{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:16Z","timestamp":1787022076723,"version":"build-2736575974"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>In Australian prisons approximately 20% of inmates are chronically infected with hepatitis C virus (HCV), providing an important population for targeted treatment and prevention. A dynamic mathematical model of HCV transmission was used to assess the impact of increasing direct-acting antiviral (DAA) treatment uptake on HCV incidence and prevalence in the prisons in New South Wales, Australia, and to assess the cost-effectiveness of alternate treatment strategies. We developed four separate models reflecting different average prison lengths of stay (LOS) of 2, 6, 24, and 36 months. Each model considered four DAA treatment coverage scenarios of 10% (status-quo), 25%, 50%, and 90% over 2016\u20132045. For each model and scenario, we estimated the lifetime burden of disease, costs and changes in quality-adjusted life years (QALYs) in prison and in the community during 2016\u20132075. Costs and QALYs were discounted 3.5% annually and adjusted to 2015 Australian dollars. Compared to treating 10% of infected prisoners, increasing DAA coverage to 25%, 50%, and 90% reduced HCV incidence in prisons by 9\u201333% (2-months LOS), 26\u201365% (6-months LOS), 37\u201370% (24-months LOS), and 35\u201365% (36-months LOS). DAA treatment was highly cost-effective among all LOS models at conservative willingness-to-pay thresholds. DAA therapy became increasingly cost-effective with increasing coverage. Compared to 10% treatment coverage, the incremental cost per QALY ranged from $497-$569 (2-months LOS), -$280\u2013$323 (6-months LOS), -$432\u2013$426 (24-months LOS), and -$245\u2013$477 (36-months LOS). Treating more than 25% of HCV-infected prisoners with DAA therapy is highly cost-effective. This study shows that treating HCV-infected prisoners is highly cost-effective and should be a government priority for the global HCV elimination effort.<\/jats:p>","DOI":"10.1371\/journal.pone.0245896","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T18:38:16Z","timestamp":1613068696000},"page":"e0245896","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-6694","authenticated-orcid":true,"given":"Jisoo A.","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0215-3249","authenticated-orcid":true,"given":"Georgina M.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamin","family":"Kinathil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hla-Hla","family":"Thein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willings","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-706X","authenticated-orcid":true,"given":"Lorraine","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"pone.0245896.ref001","unstructured":"The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. UNSW Sydney; 2018."},{"issue":"1","key":"pone.0245896.ref002","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/jvh.13013","article-title":"Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study","volume":"26","author":"JA Kwon","year":"2019","journal-title":"J Viral Hepat"},{"issue":"3","key":"pone.0245896.ref003","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","article-title":"Natural history of hepatitis C","volume":"9","author":"DL Thomas","year":"2005","journal-title":"Clin Liver Dis"},{"issue":"3","key":"pone.0245896.ref004","article-title":"Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection","volume":"146","author":"EJ Gane","year":"2014","journal-title":"Gastroenterology"},{"issue":"9916","key":"pone.0245896.ref005","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"E Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"pone.0245896.ref006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"F Poordad","year":"2013","journal-title":"N Eng J Med"},{"issue":"27","key":"pone.0245896.ref007","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"JJ Feld","year":"2015","journal-title":"N Eng J Med"},{"issue":"12","key":"pone.0245896.ref008","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/jvh.12998","article-title":"A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU\/EEA","volume":"25","author":"H Vroling","year":"2018","journal-title":"J Viral Hepat"},{"issue":"4","key":"pone.0245896.ref009","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2468-1253(16)30075-9","article-title":"Hepatitis C treatment as prevention: evidence, feasibility, and challenges","volume":"1","author":"B Hajarizadeh","year":"2016","journal-title":"T Lancet Gastroenterol Hepatol"},{"issue":"8658","key":"pone.0245896.ref010","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(89)90485-6","article-title":"Hepatitis C virus antibodies among risk groups in Spain","volume":"2","author":"JI Esteban","year":"1989","journal-title":"Lancet"},{"issue":"5","key":"pone.0245896.ref011","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/BF00209538","article-title":"Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland","volume":"9","author":"D Vlahov","year":"1993","journal-title":"Eur J Epidemiol"},{"issue":"6975","key":"pone.0245896.ref012","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/bmj.310.6975.285","article-title":"Spread of bloodborne viruses among Australian prison entrants","volume":"310","author":"N Crofts","year":"1995","journal-title":"BMJ"},{"issue":"4","key":"pone.0245896.ref013","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1467-842X.1999.tb01278.x","article-title":"Seroprevalence of markers for hepatitis B, C and G in male and female prisoners\u2014NSW, 1996","volume":"23","author":"T Butler","year":"1999","journal-title":"Aust N Z J Public Health"},{"issue":"10","key":"pone.0245896.ref014","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/add.12643","article-title":"A prospective study of hepatitis C incidence in Australian prisoners","volume":"109","author":"F Luciani","year":"2014","journal-title":"Addiction"},{"issue":"9","key":"pone.0245896.ref015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/jvh.12701","article-title":"Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005\u20132014: The HITS-p study","volume":"24","author":"EB Cunningham","year":"2017","journal-title":"J Viral Hepat"},{"issue":"1","key":"pone.0245896.ref016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1753-6405.2007.00009.x","article-title":"The 2004 Australian prison entrants\u2019 blood-borne virus and risk behaviour survey","volume":"31","author":"T Butler","year":"2007","journal-title":"Aust N Z J Public Health"},{"key":"pone.0245896.ref017","unstructured":"HCVPWG (Hepatitis C Virus Projections Working Group). Estimates and projections of the hepatitis C virus epidemic in Australia: NCHECR, UNSW; 2006 [Available from: https:\/\/webarchive.nla.gov.au\/awa\/20110403211623\/https:\/\/www.health.gov.au\/internet\/publications\/publishing.nsf\/Content\/phd-hepc-estimates-project-06-l."},{"key":"pone.0245896.ref018","unstructured":"Australian Bureau of Statistics (ABS). Prisoners in Australia 2020 [Available from: https:\/\/www.abs.gov.au\/statistics\/people\/crime-and-justice\/prisoners-australia\/latest-release#data-download."},{"key":"pone.0245896.ref019","unstructured":"Butler T, Simpson M. National Prison Entrants\u2019 Blood-Borne Virus Survey Report 2004, 2007, 2010, 2013, and 2016. Kirby Institute (UNSW Sydney). 2017. [Available from: https:\/\/kirby.unsw.edu.au\/sites\/default\/files\/kirby\/report\/JHP_National-Prison-Entrants-Report-2004-2007-2010-2013-2016.pdf]."},{"key":"pone.0245896.ref020","unstructured":"The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report UNSW; 2016 [Available from: https:\/\/kirby.unsw.edu.au\/report\/annual-surveillance-report-hiv-viral-hepatitis-stis-2016."},{"issue":"9","key":"pone.0245896.ref021","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5694\/j.1326-5377.2010.tb03605.x","article-title":"Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C","volume":"192","author":"L Boonwaat","year":"2010","journal-title":"Med J Aust"},{"issue":"8","key":"pone.0245896.ref022","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/cid\/cis1202","article-title":"Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting","volume":"56","author":"AR Lloyd","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pone.0245896.ref023","doi-asserted-by":"crossref","DOI":"10.5694\/mja2.50140","article-title":"Scale-up of hepatitis C treatment in prisons is key to national elimination","volume":"210","author":"T Papaluca","year":"2019","journal-title":"Med J Aust"},{"issue":"5659","key":"pone.0245896.ref024","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.1094442","article-title":"Uses and abuses of mathematics in biology","volume":"303","author":"RM May","year":"2004","journal-title":"Science"},{"key":"pone.0245896.ref025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.orhc.2019.04.001","article-title":"Comparing Markov and non-Markov alternatives for cost-effectiveness analysis: Insights from a cervical cancer case","volume":"21","author":"C del Campo","year":"2019","journal-title":"Operations Research for Health Care"},{"key":"pone.0245896.ref026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.drugpo.2019.02.013","article-title":"Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting","volume":"72","author":"K Overton","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"1","key":"pone.0245896.ref027","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.26639","article-title":"The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection","volume":"59","author":"J Grebely","year":"2014","journal-title":"Hepatology"},{"key":"pone.0245896.ref028","unstructured":"PayScale. Salary Data & Career Research Center (Australia) [Available from: https:\/\/www.payscale.com\/research\/AU\/Country=Australia\/Salary."},{"issue":"2","key":"pone.0245896.ref029","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jhep.2017.03.035","article-title":"Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030","volume":"67","author":"GJ Dore","year":"2017","journal-title":"J Hepatol"},{"key":"pone.0245896.ref030","unstructured":"Australian Government department of Health. MBS Online: Medicare Benefits Schedule [Available from: http:\/\/www.mbsonline.gov.au\/internet\/mbsonline\/publishing.nsf\/Content\/Home."},{"key":"pone.0245896.ref031","unstructured":"Australian government department of Health. The Pharmaceutical Benefit Scheme [Available from: https:\/\/www.pbs.gov.au\/browse\/medicine-listing."},{"key":"pone.0245896.ref032","unstructured":"Commonwealth of Australia. National Hospital Cost Data Collection Australian Public Hospitals Cost Report, Round 11. 2015."},{"key":"pone.0245896.ref033","unstructured":"The Pharmaceutical Benefits Advisory Committee (PBAC). Overview and rationale of the economic evaluation 2016 [Available from: https:\/\/pbac.pbs.gov.au\/section-3a\/3a-1-overview-and-rationale-of-economic-evaluation.html."},{"issue":"1","key":"pone.0245896.ref034","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.27151","article-title":"Cost analysis of sofosbuvir\/ribavirin versus sofosbuvir\/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible\/intolerant individuals","volume":"60","author":"LM Hagan","year":"2014","journal-title":"Hepatology"},{"issue":"2","key":"pone.0245896.ref035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40273-017-0585-2","article-title":"Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System","volume":"36","author":"LC Edney","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"pone.0245896.ref036","unstructured":"Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied Methods of Cost-Effectiveness Analysis in Health Care: Oxford University Press; 2011. [Available from: https:\/\/EconPapers.repec.org\/RePEc:oxp:obooks:9780199227280]."},{"key":"pone.0245896.ref037","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"AH Briggs","year":"2006"},{"key":"pone.0245896.ref038","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Hepatitis C among Drug Users in Europe: Epidemiology, Treatment and Prevention Luxembourg2016 [Available from: https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2953\/TDXD16002ENN_final_web.pdf."},{"issue":"12","key":"pone.0245896.ref039","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jama.2012.374","article-title":"Screening for HCV infection in jails","volume":"307","author":"AC Spaulding","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"pone.0245896.ref040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/M15-0617","article-title":"Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons","volume":"164","author":"T He","year":"2016","journal-title":"Ann Intern Med"},{"issue":"8","key":"pone.0245896.ref041","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/M14-0602","article-title":"Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis","volume":"161","author":"S Liu","year":"2014","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0245896.ref042","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2013.03.008","article-title":"Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C","volume":"59","author":"A Marco","year":"2013","journal-title":"J Hepatol"},{"key":"pone.0245896.ref043","doi-asserted-by":"crossref","first-page":"102597","DOI":"10.1016\/j.drugpo.2019.11.005","article-title":"Hepatitis C reinfection in prisons with broad access to Direct Acting Antiviral treatments","volume":"77","author":"J Blogg","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"6","key":"pone.0245896.ref044","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/QCO.0000000000000216","article-title":"Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence","volume":"28","author":"M Hickman","year":"2015","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"pone.0245896.ref045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation","volume":"65","author":"NK Martin","year":"2016","journal-title":"J Hepatol"},{"key":"pone.0245896.ref046","first-page":"w14543","article-title":"Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030","volume":"147","author":"P Bruggmann","year":"2017","journal-title":"Swiss Med Wkly"},{"issue":"5","key":"pone.0245896.ref047","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/add.14830","article-title":"Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study","volume":"115","author":"NA Bretana","year":"2020","journal-title":"Addiction"},{"issue":"12","key":"pone.0245896.ref048","first-page":"1472","article-title":"Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings","volume":"25","author":"N Scott","year":"2018","journal-title":"J Hepatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T22:32:46Z","timestamp":1724452366000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245896"}},"subtitle":[],"editor":[{"given":"Yury E.","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0245896","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}